Singh Binayak, Manita Bai, Suman Fnu, Kumari Nikita, Shiza Saher T, Samreen Iqra, Shah Siddhi, Mokhtar Saria M, Patel Utsav, Devi Joti, Reza Rezaur Rahman, Mohamed Khalid H, Ahmad Sarfaraz, Nasir Hira
Medicine, Mayo Hospital, Lahore, PAK.
Internal Medicine, Ghulam Muhammad Mahar Medical College, Sukkur, PAK.
Cureus. 2023 Dec 11;15(12):e50319. doi: 10.7759/cureus.50319. eCollection 2023 Dec.
Takotsubo cardiomyopathy (TCM) is a life-threatening transient left ventricular dysfunction triggered by either physical or emotional stressors. Concerns have been raised on reports of TCM after the coronavirus disease 2019 (COVID-19) vaccine. Our study provides comprehensive detail on COVID-19 vaccine-induced TCM. We conducted a systemic literature search using major databases, including PubMed, EMBASE, and Google Scholar up to November 2023, to identify cases of COVID-19 vaccine-induced TCM using the MeSH terms and keywords "covid-19 vaccines" and "takotsubo cardiomyopathy". We identified 15 case reports, including 16 patients with COVID-19 vaccine-induced TCM. The mean age was 55.81 ± 19.13 years, and 75% of the patients were female. The most common presentation was chest pain (62.5%), and the average time to first symptom onset was 3.12 ± 2.24 days. COVID-19 vaccine-induced TCM was reported in 43.75% of patients receiving the first and second dose each, and 87% of patients had messenger ribonucleic acid (mRNA) COVID-19 vaccine (Pfizer, Moderna). The elevated level of cardiac troponins was found in all the patients with a left ventricular ejection fraction (LVEF) of <50% in 15 patients, and T-wave inversion (50%) was the most common electrocardiographic finding. The mean length of the hospital stay was 7.27 ± 3.95 days, and 87% of patients were discharged. COVID-19 vaccine-induced TCM is a rare but life-threatening complication. TCM should be included in the differential diagnosis of chest pain or dyspnea in patients recently receiving the COVID-19 vaccine.
应激性心肌病（TCM）是一种由身体或情绪应激源引发的危及生命的短暂性左心室功能障碍。2019冠状病毒病（COVID-19）疫苗接种后出现应激性心肌病的报告引发了人们的担忧。我们的研究提供了关于COVID-19疫苗诱发应激性心肌病的全面详细信息。我们使用包括PubMed、EMBASE和谷歌学术在内的主要数据库进行了系统的文献检索，截至2023年11月，使用医学主题词（MeSH）术语和关键词“covid-19疫苗”和“应激性心肌病”来识别COVID-19疫苗诱发应激性心肌病的病例。我们确定了15例病例报告，包括16例COVID-19疫苗诱发应激性心肌病患者。平均年龄为55.81±19.13岁，75%的患者为女性。最常见的表现是胸痛（62.5%），首次症状出现的平均时间为3.12±2.24天。分别有43.75%接受第一剂和第二剂疫苗的患者报告出现COVID-19疫苗诱发应激性心肌病，87%的患者接种了信使核糖核酸（mRNA）COVID-19疫苗（辉瑞、莫德纳）。所有患者均发现心肌肌钙蛋白水平升高，15例患者左心室射血分数（LVEF）<50%，T波倒置（50%）是最常见的心电图表现。平均住院时间为7.27±3.95天，87%的患者出院。COVID-19疫苗诱发应激性心肌病是一种罕见但危及生命的并发症。对于近期接种COVID-19疫苗的胸痛或呼吸困难患者，应激性心肌病应纳入鉴别诊断。
